Ankush Mahajan's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q4 2024
Question
Ankush Mahajan sought to understand the reason for the sequential decrease in U.S. sales, asking if it was driven by the base business or generic Revlimid. He also requested the full-year EBITDA margin guidance for FY'25.
Answer
CEO Erez Israeli clarified that the sequential decline in U.S. sales was a combination of normal ordering patterns and some price erosion on a few products, not specific to any single product. He did not provide specific guidance for FY'25 but reiterated the company's long-term ambition to maintain a 25% EBITDA margin and 25% ROCE, noting that performance can fluctuate around this target.